Turning Point Therapeutics to Participate in Upcoming Investor Conferences
May 26 2022 - 4:30PM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage
precision oncology company designing and developing novel targeted
therapies for cancer treatment, today announced that President and
CEO Athena Countouriotis, M.D., will participate in the Jefferies
Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs
Healthcare Conference on June 14.
Dr. Countouriotis is scheduled to present a company overview in
New York on June 8 at 11 a.m. ET and scheduled to participate in a
fireside chat on June 14 in Rancho Palo Verdes, California at 1
p.m. ET.
Both sessions will be accessible via webcast through links that
will be posted to the Investors page of www.tptherapeutics.com.
About Turning Point Therapeutics
Inc.Turning Point Therapeutics is a clinical-stage
precision oncology company with a pipeline of investigational drugs
designed to address key limitations of existing cancer therapies.
The company’s lead drug candidate, repotrectinib, is a
next-generation kinase inhibitor targeting the ROS1 and TRK
oncogenic drivers of non-small cell lung cancer and advanced solid
tumors. Repotrectinib, which is being studied in a registrational
Phase 2 study in adults and a Phase 1/2 study in pediatric
patients, has shown antitumor activity and durable responses among
kinase inhibitor treatment-naïve and pre-treated patients. The
company’s pipeline of drug candidates also includes elzovantinib,
targeting MET, CSF1R and SRC, which is being studied in a Phase 1
trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in MET; TPX-0046, targeting RET,
which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; TPX-0131, a next-generation ALK inhibitor, which is being
studied in a Phase 1/2 trial of previously treated patients with
ALK-positive advanced or metastatic non-small cell lung cancer; and
TPX-4589 (LM-302), a novel ADC targeting Claudin18.2 which is being
studied in a Phase 1 study in gastrointestinal cancers. The company
is driven to develop therapies that mark a turning point for
patients in their cancer treatment. For more information,
visit www.tptherapeutics.com.
Contact: Adam D. Levy, PhD.,
MBAir@tptherapeutics.com858-867-6366
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Jul 2023 to Jul 2024